Dapagliflozin (Farxiga/AZ) – Guidelines+ Monographs (August 2024 Edition)
In this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]
Read More